184 related articles for article (PubMed ID: 26677998)
1. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
[TBL] [Abstract][Full Text] [Related]
2. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
[TBL] [Abstract][Full Text] [Related]
3. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
[TBL] [Abstract][Full Text] [Related]
4. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
5. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of rituximab in paediatric immune mediated diseases: B cell depletion and repopulation, effects on immunoglobulin levels and risk for infections.
Nassar-Sheikh Rashid A; Bergkamp SC; Kampinga RE; Gouw SC; Bouts AHM; Oosterveld MJS; Baars PA; van Leeuwen EMM; Kuijpers TW; van den Berg JM; Schonenberg-Meinema D
Clin Exp Rheumatol; 2023 Nov; 41(11):2323-2330. PubMed ID: 37470239
[TBL] [Abstract][Full Text] [Related]
7. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
[TBL] [Abstract][Full Text] [Related]
8. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
9. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
Boleto G; Avouac J; Wipff J; Forien M; Dougados M; Roux C; Kahan A; Dieude P; Allanore Y
Semin Arthritis Rheum; 2018 Oct; 48(2):149-154. PubMed ID: 29548542
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.
Einarsson JT; Evert M; Geborek P; Saxne T; Lundgren M; Kapetanovic MC
Clin Rheumatol; 2017 Dec; 36(12):2743-2750. PubMed ID: 28980088
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.
Braun-Moscovici Y; Butbul-Aviel Y; Guralnik L; Toledano K; Markovits D; Rozin A; Nahir MA; Balbir-Gurman A
Rheumatol Int; 2013 Jun; 33(6):1495-504. PubMed ID: 23239037
[TBL] [Abstract][Full Text] [Related]
12. A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.
Stradner MH; Dejaco C; Brickmann K; Graninger WB; Brezinschek HP
Arthritis Res Ther; 2016 Aug; 18(1):190. PubMed ID: 27558631
[TBL] [Abstract][Full Text] [Related]
13. Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.
Veeken LD; Opdam MAA; Verhoef LM; Popa C; van Crevel R; den Broeder AA
Rheumatology (Oxford); 2024 May; 63(5):1246-1250. PubMed ID: 37410085
[TBL] [Abstract][Full Text] [Related]
14. Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study.
Dumusc A; Alromaih F; Perreau M; Hügle T; Zufferey P; Dan D
Arthritis Res Ther; 2023 Jun; 25(1):91. PubMed ID: 37264414
[TBL] [Abstract][Full Text] [Related]
15. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab.
de la Torre I; Leandro MJ; Edwards JC; Cambridge G
Clin Exp Rheumatol; 2012; 30(4):554-60. PubMed ID: 22510323
[TBL] [Abstract][Full Text] [Related]
16. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
Scotti B; Disanto G; Sacco R; Guigli M; Zecca C; Gobbi C
PLoS One; 2018; 13(5):e0197415. PubMed ID: 29758075
[TBL] [Abstract][Full Text] [Related]
18. Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab.
Tony HP; Roll P; Mei HE; Blümner E; Straka A; Gnuegge L; Dörner T;
Clin Exp Rheumatol; 2015; 33(6):887-94. PubMed ID: 26517829
[TBL] [Abstract][Full Text] [Related]
19. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2014 Oct; 53(10):1818-24. PubMed ID: 24831059
[TBL] [Abstract][Full Text] [Related]
20. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.
Henry J; Gottenberg JE; Rouanet S; Pavy S; Sellam J; Tubach F; Belkhir R; Mariette X; Seror R;
Rheumatology (Oxford); 2018 Mar; 57(3):538-547. PubMed ID: 29267905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
